FAIR VALUE DISCLOSURES - Narrative (Details)						3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2024 USD ($)	Sep. 16, 2024 USD ($) $ / shares	Feb. 22, 2024 USD ($)	Dec. 12, 2023 USD ($)	May 17, 2021 USD ($)	Sep. 30, 2024 USD ($) guarantee	Sep. 30, 2024 USD ($) guarantee	Sep. 30, 2023 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jan. 24, 2024 shares	Dec. 31, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money Market Fund						$ 83,304,000	$ 83,304,000					$ 191,841,000
Interest rate swap						3,556,000	$ 3,556,000					6,236,000
Achievement of milestones payment period							24 months
Payments on contingent consideration							$ 12,500,000	$ 0
Contingent consideration, Novitium						12,800,000	12,800,000					24,000,000.0
Novitium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Additional contingent consideration						46,500,000	46,500,000
Payments on contingent consideration			$ 12,500,000	$ 12,500,000
Contingent consideration, Novitium						12,758,000	12,758,000					$ 23,984,000
Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Common Stock, par value (in dollars per share) | $ / shares		$ 0.01
Business combination, milestone payment multiplier		0.25
Contingent consideration, Novitium						8,700,000	8,700,000
CG Oncology
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Shares held (in shares) | shares											219,925
Closing price						$ 37.73	$ 37.73
Accrued Licensor Payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Up-front payment					$ 75,000,000
Number of quarterly guaranteed payment | guarantee						3	3
Additional milestone payment							$ 5,600,000
Fair value of payments						$ 8,300,000	8,300,000
Accrued Licensor Payments | Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Additional milestone payment										$ 7,500,000
Collaborative arrangement royalty payable on net revenue revenue threshold									$ 70,000,000
Eye Point Agreements Member
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Payments for royalties						1,900,000
Fair value of payments						23,100,000	23,100,000
Eye Point Agreements Member | Forecast
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Payments for royalties	$ 1,900,000
Alimera Sciences, Inc | Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration classified as equity, fair value disclosure						$ 8,700,000	$ 8,700,000
2026 Milestone Revenue Payment | Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, divisible revenue		$ 10,000,000
2026 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, milestone payment, revenue achievement		$ 140,000,000.0
Business combination, milestone payment multiplier		0.25
Business combination, divisible revenue		$ 10,000,000
2027 Milestone Revenue Payment | Alimera Sciences, Inc
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, divisible revenue		15,000,000
2027 Milestone Revenue Payment | Alimera Sciences, Inc | Contingent Value Rights Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, milestone payment, revenue achievement		$ 160,000,000.0
Business combination, milestone payment multiplier		0.25
Business combination, divisible revenue		$ 15,000,000
Contingent consideration, milestone payment, CVRs agreement business days		15 days